Author Topic: (Abst.) Adverse event profile differences between Rituxan and Ocrevus...  (Read 130 times)

0 Members and 1 Guest are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9822
  • MS diagnosed 1980
  • Location: Pacific Northwest
From Multiple Sclerosis Journal (August 24, 2020), "Adverse event profile differences between rituximab and ocrelizumab: Findings from the FDA Adverse Event Reporting Database":


https://journals.sagepub.com/doi/abs/10.1177/1352458520949986



MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.

Offline agate

  • Administrator
  • *****
  • Posts: 9822
  • MS diagnosed 1980
  • Location: Pacific Northwest
More on this in Multiple Sclerosis News Today (August 26, 2020)--"MS infection risk for Ocrevus higher than Rituximab but cancer risk lower":


https://bit.ly/2YDIxmm
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.

 

Related Topics

  Subject / Started by Replies Last post
1 Replies
238 Views
Last post June 14, 2017, 10:35:24 am
by agate
0 Replies
80 Views
Last post October 05, 2019, 07:51:03 am
by agate
0 Replies
48 Views
Last post September 17, 2021, 08:18:27 pm
by agate
0 Replies
1136 Views
Last post November 13, 2023, 09:20:11 pm
by agate
0 Replies
5 Views
Last post January 23, 2024, 08:31:15 am
by agate